Business
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2024 and provided clinical and corporate updates.
About this update from Calcimedica, Inc.
[{"type":"text","content":"Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo","length":253,"tagName":"p","attribs":{}},{"type":"text","content":"Cash position expected to fund operations into mid-2026","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2024 and provided clinical and corporate updates.","length":452,"tagName":"p"},{"type":"image","alt":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","displaySize":"","headline":null,"caption":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":78,"url":"https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OrsqdcERGNiUdevuO33D2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae","width":400,"height":78}},"href":"https://mma.prnewswire.com/media/685404/calcimedica_v3.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Enrollment in our Phase 2 KOURAGE trial is on track to deliver data around the end of 2025," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "Looking ahead to the KOURAGE readout, we are further encouraged by the promising readthrough from the data recently presented at the 30th International AKI & CRRT Conference, which show a 62.7% relative reduction in mortality in CARDEA patients with both kidney failure and respiratory failure, mirroring KOURAGE's patient population. With th...